Journal
CLINICAL INFECTIOUS DISEASES
Volume 73, Issue 6, Pages E1372-E1375Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/ciab302
Keywords
Daratumumab; hepatitis B virus; reactivation; multiple myeloma
Categories
Funding
- Research Fund of Seoul St. Mary's Hospital, The Catholic University of Korea
- Research Supporting Program of The Korean Association for the Study of the Liver
- Korean Liver Foundation
Ask authors/readers for more resources
Among multiple myeloma patients who are HBsAg-negative and receiving daratumumab treatment, there is a significant risk of reactivation of resolved HBV.
The risk of reactivation of resolved hepatitis B virus (HBV) in hepatitis B surface antigen (HBsAg)-negative multiple myeloma patients after daratumumab has not been reported. Among 93 patients with daratumumab treatment, reactivation occurred in 6 patients (6.5%) with one hepatic failure. This is the first report demonstrating a considerable risk of reactivation of resolved HBV after daratumumab.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
